nafamostat has been researched along with Respiratory Insufficiency in 5 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Respiratory Insufficiency: Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " infusion performed 1 h after intrabiliary injection of enterokinase/sodium taurocholate to induce acute pancreatitis (AP): (1) Saline; (2) 5 micrograms/kg/h nafamostat mesilate (FUT-175); (3) 10 micrograms/kg/h FUT-175; and (4) 25 micrograms/kg/h FUT-175." | 7.69 | Nafamostat mesilate on the course of acute pancreatitis. Protective effect on peritoneal permeability and relation with supervening pulmonary distress. ( Chui, DH; Fesce, E; Idéo, G; Marotta, F; Rezakovic, I; Suzuki, K, 1994) |
| " infusion performed 1 h after intrabiliary injection of enterokinase/sodium taurocholate to induce acute pancreatitis (AP): (1) Saline; (2) 5 micrograms/kg/h nafamostat mesilate (FUT-175); (3) 10 micrograms/kg/h FUT-175; and (4) 25 micrograms/kg/h FUT-175." | 3.69 | Nafamostat mesilate on the course of acute pancreatitis. Protective effect on peritoneal permeability and relation with supervening pulmonary distress. ( Chui, DH; Fesce, E; Idéo, G; Marotta, F; Rezakovic, I; Suzuki, K, 1994) |
| "We treated two patients with severe respiratory failure due to coronavirus disease 2019 (COVID-19)." | 2.66 | High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19. ( Fujii, H; Hiraoka, N; Horiguchi, M; Matsuyama, A; Omura, A; Ono, S; Shiotsu, S; Suga, Y; Takumi, C; Tanaka, S; Tsuji, T; Yuba, T, 2020) |
| "Nafamostat mesilate was used as the main anticoagulant with a small amount of heparin." | 1.29 | Extracorporeal membrane oxygenation for respiratory failure. ( Arai, K; Ishikawa, S; Kunimoto, F; Morishita, Y; Otaki, A; Otani, Y; Sato, Y; Takahashi, T; Yamagishi, T; Yoshida, I, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, H | 1 |
| Tsuji, T | 1 |
| Yuba, T | 1 |
| Tanaka, S | 1 |
| Suga, Y | 1 |
| Matsuyama, A | 1 |
| Omura, A | 1 |
| Shiotsu, S | 1 |
| Takumi, C | 1 |
| Ono, S | 1 |
| Horiguchi, M | 1 |
| Hiraoka, N | 1 |
| Iwasaka, S | 1 |
| Shono, Y | 1 |
| Tokuda, K | 1 |
| Nakashima, K | 1 |
| Yamamoto, Y | 1 |
| Maki, J | 1 |
| Nagasaki, Y | 1 |
| Shimono, N | 1 |
| Akahoshi, T | 1 |
| Taguchi, T | 1 |
| Kotani, K | 1 |
| Ichiba, S | 1 |
| Andou, M | 1 |
| Sano, Y | 1 |
| Date, H | 1 |
| Tedoriya, T | 1 |
| Goto, K | 1 |
| Shimizu, N | 1 |
| Marotta, F | 1 |
| Fesce, E | 1 |
| Rezakovic, I | 1 |
| Chui, DH | 1 |
| Suzuki, K | 1 |
| Idéo, G | 1 |
| Yamagishi, T | 1 |
| Ishikawa, S | 1 |
| Otaki, A | 1 |
| Otani, Y | 1 |
| Takahashi, T | 1 |
| Sato, Y | 1 |
| Yoshida, I | 1 |
| Kunimoto, F | 1 |
| Arai, K | 1 |
| Morishita, Y | 1 |
1 review available for nafamostat and Respiratory Insufficiency
| Article | Year |
|---|---|
High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : High levels of anti-SSA/Ro antibodies in COVID-19.
Topics: Aged; Amides; Antibodies, Antinuclear; Antiviral Agents; Benzamidines; Betacoronavirus; Coronavirus | 2020 |
4 other studies available for nafamostat and Respiratory Insufficiency
| Article | Year |
|---|---|
Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Benzamidines; Betacoronavirus; Coro | 2020 |
Extracorporeal membrane oxygenation with nafamostat mesilate as an anticoagulant for massive pulmonary hemorrhage after living-donor lobar lung transplantation.
Topics: Acute Disease; Adult; Anticoagulants; Benzamidines; Combined Modality Therapy; Extracorporeal Membra | 2002 |
Nafamostat mesilate on the course of acute pancreatitis. Protective effect on peritoneal permeability and relation with supervening pulmonary distress.
Topics: Acute Disease; Animals; Benzamidines; Dextrans; Fluorescein-5-isothiocyanate; Guanidines; Male; Panc | 1994 |
Extracorporeal membrane oxygenation for respiratory failure.
Topics: Adult; Aged; Antithrombins; Benzamidines; Carbon Dioxide; Child; Child, Preschool; Extracorporeal Me | 1995 |